[go: up one dir, main page]

NO972522L - Monoclonal antibodies with immunosuppressive activity - Google Patents

Monoclonal antibodies with immunosuppressive activity

Info

Publication number
NO972522L
NO972522L NO972522A NO972522A NO972522L NO 972522 L NO972522 L NO 972522L NO 972522 A NO972522 A NO 972522A NO 972522 A NO972522 A NO 972522A NO 972522 L NO972522 L NO 972522L
Authority
NO
Norway
Prior art keywords
fragments
mab
monoclonal antibodies
fab
immunosuppressive activity
Prior art date
Application number
NO972522A
Other languages
Norwegian (no)
Other versions
NO972522D0 (en
Inventor
Zoltan Nagy
Damir Vidovic
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO972522D0 publication Critical patent/NO972522D0/en
Publication of NO972522L publication Critical patent/NO972522L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Oppfinnelsen omfatter enverdige mAb-fragmenter (Fab) av mAb, som har evnen til å nedregulere HLA-DR-ekspresjonen på antigenpresenterende celler. Fab-frag- mentene kan nedregulere denne HLA-DR-ekspreejon uten å utøve cytotoksisiteten som observeres hos stam- mAb'et eller av de toverdige fragmenter (F(ab)'2) av det monoklonale antistoff. Fab-fragmentene ifølge oppfinnelsen er derfor sterke MHC-klasse Il-spesifik- ke immunosuppressive forbindelser uten cytotoksiske bivirkninger.The invention comprises monovalent mAb fragments (Fab) of mAb, which have the ability to down-regulate HLA-DR expression on antigen presenting cells. The Fab fragments can down-regulate this HLA-DR expression without exerting the cytotoxicity observed in the stem mAb or of the bivalent fragments (F (ab) '2) of the monoclonal antibody. The Fab fragments of the invention are therefore strong MHC class II specific immunosuppressive compounds without cytotoxic side effects.

NO972522A 1994-12-07 1997-06-03 Monoclonal antibodies with immunosuppressive activity NO972522L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35091594A 1994-12-07 1994-12-07
PCT/EP1995/004648 WO1996017874A1 (en) 1994-12-07 1995-11-25 Monoclonal antibody fragments having immunosuppressant activity

Publications (2)

Publication Number Publication Date
NO972522D0 NO972522D0 (en) 1997-06-03
NO972522L true NO972522L (en) 1997-08-06

Family

ID=23378740

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972522A NO972522L (en) 1994-12-07 1997-06-03 Monoclonal antibodies with immunosuppressive activity

Country Status (19)

Country Link
EP (1) EP0787151A1 (en)
JP (1) JP2001506122A (en)
CN (1) CN1168679A (en)
AR (1) AR002005A1 (en)
AU (1) AU4256096A (en)
BR (1) BR9509902A (en)
CA (1) CA2206471A1 (en)
CO (1) CO4480041A1 (en)
CZ (1) CZ172497A3 (en)
FI (1) FI972430A0 (en)
HU (1) HUT77342A (en)
IL (1) IL116228A0 (en)
MA (1) MA23739A1 (en)
NO (1) NO972522L (en)
PE (1) PE52996A1 (en)
PL (1) PL320610A1 (en)
TR (1) TR199501542A2 (en)
WO (1) WO1996017874A1 (en)
ZA (1) ZA9510195B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
AU5588099A (en) 1998-08-28 2000-03-21 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
DE60035337T2 (en) * 2000-05-12 2008-02-28 Gpc Biotech Ag Human peptides / proteins that cause or cause the killing of cells, including lymphoid tumor cells
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
EP1156062A1 (en) * 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
US20030082188A1 (en) 2001-10-11 2003-05-01 Tso J. Yun Treatment of prostate cancer by inhibitors of NCAM2
EP1369431A4 (en) 2001-10-15 2005-01-12 Kirin Brewery Anti-hla-dr antibody
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2011123428A1 (en) * 2010-04-01 2011-10-06 Immunomedics, Inc. Antibody-based depletion of antigen-presenting cells and dendritic cells
KR102647825B1 (en) * 2021-07-22 2024-03-14 서울대학교산학협력단 Anti-HLA-DP monoclonal antibody and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3269354D1 (en) * 1981-06-25 1986-04-03 Univ Leland Stanford Junior Allele specific immunotherapeutic method and dosage form
CA2070182C (en) * 1989-12-27 2002-12-24 John Ghrayeb Chimeric immunoglobulin for cd4 receptors
NZ243706A (en) * 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions

Also Published As

Publication number Publication date
AU4256096A (en) 1996-06-26
FI972430A7 (en) 1997-06-06
PE52996A1 (en) 1996-12-12
NO972522D0 (en) 1997-06-03
MA23739A1 (en) 1996-07-01
FI972430L (en) 1997-06-06
TR199501542A2 (en) 1996-07-21
IL116228A0 (en) 1996-03-31
CA2206471A1 (en) 1996-06-13
MX9704225A (en) 1997-09-30
WO1996017874A1 (en) 1996-06-13
CO4480041A1 (en) 1997-07-09
CN1168679A (en) 1997-12-24
JP2001506122A (en) 2001-05-15
ZA9510195B (en) 1996-06-07
HUT77342A (en) 1998-03-30
AR002005A1 (en) 1998-01-07
FI972430A0 (en) 1997-06-06
CZ172497A3 (en) 1997-10-15
PL320610A1 (en) 1997-10-13
EP0787151A1 (en) 1997-08-06
BR9509902A (en) 1997-10-21

Similar Documents

Publication Publication Date Title
ATE208820T1 (en) HUMANIZED ANTIBODIES
WO1998057994A3 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
DK0673418T3 (en) Monoclonal antibodies directed against microtubule-associated tau protein, hybridomas secreting these antibodies, antigen
ZA945364B (en) Antibodies specific for human prostate glandular kallikrein
BR9713521A (en)
EP0677533A3 (en) Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
CA2212150A1 (en) Monoclonal antibodies for human osteogenic cell surface antigens
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
DK0969873T3 (en) Multiple carbohydrate-containing glycopeptide antigens, vaccine containing them, and use thereof
DK0845998T3 (en) Immunotherapy drugs containing antibodies that specifically recognize the MHCII antigen in a patient to be treated
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
NO972522L (en) Monoclonal antibodies with immunosuppressive activity
CA2137638A1 (en) Anti Gangliosides Monoclonal Antibodies and Their Use in the Specific Active Immunotherapy of Malignant Tumors
GR3029483T3 (en) Antibodies against t-cells as therapeutics
CA2036814A1 (en) Monoclonal antibodies against tumor-associated antigens, a process for the preparation thereof and the use thereof
ES2119992T3 (en) SPECIFIC ANTIBODIES OF 6-O-METHYLGUANIN-DNA-METHYL TRANSFERASE (MGMT).
PL314414A1 (en) Antiidiotypic antibodies capable to induce an immunological response in respect to the receptor of epidermis growth factor
NO962827D0 (en) Monoclonal antibodies to antigens expressed by hematopoietic facilitatory cells
BR9702101A (en) Hybridoma and monoclonal antibody
AU1626492A (en) Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof
ECSP951605A (en) FRAGMENTS OF MONOCLONAL ANTIBODIES THAT HAVE IMMUNOSUPPRESSIVE ACTIVITY, CASE RAN 4105/171
EP0450573A3 (en) Antibodies for the treatment and diagnosis of pseudomonas aeruginosa infections
刘亚霞 et al. ISOLATION AND STUDY OF THE CD2 ANTIGEN PURIFIED BY AFFINITY CHROMATOGRAPHY WITH OKT11-LIKE MAB
ES2088820A1 (en) Antipneumolysin monoclonal antibodies